Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + R-CHOP in Untreated ABC-DLBCL
NCT03731234Phase 2Active, not recruiting
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jul 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-Free Survival at 48 months. Started Jul 2019; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03731234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03731234.